To determine whether telaglenastat could suppress mTOR pathway activity in RCC, we measured phosphorylation of S6 and 4E-BP1, markers of mTOR activation, across 6 ccRCC cell lines. This evidence concerns the gene EIF4EBP1 and nonpapillary renal cell carcinoma.